Maria Alfaiate will join Lundbeck on 1 August 2024 and will be part of the Executive Management team.

Maria Alfaiate will be responsible for strengthening corporate strategic functions and enhancing global marketing efforts. Her focus will be on optimizing Lundbeck’s ability to capitalize on both present and future opportunities. She brings significant experience from the life science and pharmaceutical sectors globally, states Lundbeck. Her expertise in developing strategic plans and executing programs to deliver state-of-the-art solutions for patients across diverse markets will play a pivotal role in shaping Lundbeck’s future growth, it states.

Maria Alfaiate

Maria Alfaiate joins Lundbeck from Bayer where she recently served as Senior Vice President and Global Head of New Products Commercialization and Portfolio Strategy. Prior to this, she has held positions at AstraZeneca and MSD/ Merck, in global teams but also at country level. She is of Portuguese nationality and holds a Master of Clinical Psychology from Universidade de Coimbra, Portugal.

“Embarking on this new journey, I am fueled by the possibilities ahead and the opportunity to be impactful. I am joining a remarkable group of individuals devoted to helping patients suffering from neurological or psychiatric conditions. The vision of making a positive contribution to people and society resonates tremendously at a personal level,” says Maria Alfaiate.

Photo: PR Photo